Kymera Therapeutics, Inc. · NASDAQ:KYMR

Kymera Therapeutics — Technical Presentation (June 2021)

13 slides from Kymera Therapeutics's technical presentation, June 2021

  1. Slide 1: Non-interventional Study of IRAK4 and Inflammatory Transcriptomics in Skin Diseases

    !"#$%&#'(!')%*$+,-(+.(/0.#*11*$%+0(2+,,'#*$'(3%$4(/5678(9:&,'--%+0( %0($4'(;<%0(+.(=%),*)'0%$%-(;"&&",*$%>*(?*$%'0$-(*0)(*,'(@#+A<')(BC($4'( /5678(D'E,*)',(7FG8H8(%0(FI5G*A$%>*$')(!+0+AC$'- 6.-*0'4(6#*>%!"#$%&'()*"+*,-.$//!"0/()$"1)2&'*/3!"45$-6*'($"47&8%*9!" :$;;%$<"2*=(9!"0'56&'<"4/*=('!">*68/"?*%

  2. Slide 2: Forward-Looking Statements

    J+,3*,)G#++<%0E(;$*$'1'0$- M6(9"-%$9$'5*5(&'"*'3"95*5$,$'59",*3$"&%*//<"38%('C"56(9"-%$9$'5*5(&'")&'5*('";&%R*%3H/&&7('C"95*5$,$'59"R(56('"56$",$*'('C"&;"56$"O%(=*5$"4$)8%(5($9"S(5(C*5(&'">$;&%," 0)5"&;"FTTU"VO4S>0W"*'3"&56$%";$3$%*/"9$)8%(5($9"/*R9Q"M6$9$"95*5$,$'59"(')/83$".$/($;9"*'3")&')/89(&'9"

  3. Slide 3: Financial Disclosures

    J%0*0A%*#(D%-A#+-",'- 6.-*0'4(6#*>% 2%Q"0/*=("6*9".$$'"('=$95(C*5&%"*'3"%$)$(=$3"6&'&%*%(*";%&,"0..#($!"0%)85(9!"b14!"b&$6%('C$%H B'C$/6$(,!"b*89)6!"+$/C$'$"!"2$%,(%*!"2$%,&=*'5!"24b(&-6*%,*!"L/("S(//<!"L12"4$%&'&!" A*/3$%,*!"A/$',*%7!"A4?!"B')<5$!"B/7&9!":*'99$'!"SLc"O6*%,*!"?<&R*"?(%('!"?<,$%*!"1$

  4. Slide 4: General Role of IRAK4 in Inflammation and KT-474 Degradation

    2'0$,*#(5+#'(+.(/5678(%0(FI5P/IGQ5(?*$43*C(6A$%>*$%+0 2$=$/&-,$'5"&;"?<,$%* B>0?X"3$C%*3$%"?MHXeX BSHFYBSHFIYBSHGGYBSHGh • B>0?X"(9"*"7$<")&,-&'$'5"&;"56$"1C))+-+1' A+1&#':( ,$3(*5('C"9(C'*/('C"56%&8C6"MS>9"*'3"BSHF>9 FI5- /IGQ5- • b&56"56$"-A*..+#)%0E *'3"<%0*-' ;8')5(&'9"&;"B>0?X"*%$" ('=&/=$3"('"

  5. Slide 5: Non-Interventional Study of KT-474 and Inflammatory Biomarkers in HS and AD Patients Design

    N+0G%0$',>'0$%+0*#(;$")C(+.(/5678(*0)(/0.#*11*$+,C(@%+1*,<',- %0(=;(*0)(6D(?*$%'0$- D'-%E0 @*-'#%0'(D'1+E,*&4%A-(V(@%+1*,<',- 4('C/$")$'5$%"VK&%7"2$%,*5&/&C<"+/('()"*'3">$9$*%)6"+$'5$%!"c'5*%(&!" ;$")C • gOBf"DI1*<DEDE N"1B',(+.(;%$'- +*'*3*W D",*$%+0 • N4"*'3"02"*))%8*/")&,-/$5$3f"DX1*%DEDF OBf"2%Q

  6. Slide 6: Methods for Testing Skin Biopsies and Transcriptomic Profiling

    !'$4+)-(.+,(!'*-",%0E /5678(?,+$'%0(*0)(?,+G/0.#*11*$+,C(O'0'( F,*0-A,%&$-(%0(=;(;<%0(@%+&-%'-(*0)(='*#$4C(;"BW'A$(;<%0P!+0+AC$'- N/(;$")C(!'$4+)- 2+0$,+#(!'$4+)- N4"47('"b(&-9($9"V@nGEW N$*/56<"48.[$)5"47('"b(&-9($9"V@nFEW S$9(&'"VSW!"O$%(H/$9(&'"VOSW!"@&'H/$9(&'"V@SW /5678 /5678 /11"0+.#"+,'-A'0A'

  7. Slide 7: IRAK4 Protein Expression Is Elevated in HS Skin Lesions

    /5678(?,+$'%0(9:&,'--%+0(%-(9#'>*$')(%0(=;(;<%0(2+1&*,')( $+(;<%0(.,+1(='*#$4C(;"BW'A$- /11"0+.#"+,'-A'0A'(S/JU !*--(;&'A$,+1'$,C(S!;U • +&')&%3*')$".$5R$$'"Bg" *'3"14";&%"N4"-*5($'59" • N4"-*5($'59f"S$9(&'"m" O$%(H/$9(&'"m"@&'H/$9(&' • Bg"96&R9"9(C'(;()*'5" 3(;;$%$')$".$5R$$'"N4" @&'H/$9(&'"97('"*'

  8. Slide 8: IRAK4 Is Upregulated in Dermis and Epidermis of HS Patients Relative to Healthy Subjects

    /5678(%-(Y&,'E"#*$')(%0(D',1%-(*0)(9&%)',1%-(+.(=;(?*$%'0$-(5'#*$%>'( $+(;<%0(+.(='*#$4C(;"BW'A$- D',1*#(/11"0'(2'##- S$9(&' O$%(H/$9(&' @&'H/$9(&' N$*/56<"98.[$)5 =%-$+#+EC NrL 9&%)',1*#(7',*$%0+AC$'- /J(;$*%0 @8)/$*% B>0?X !+,&4+#+EC( • Bg"96&R9"(')%$*9$3"'8,.$%"&;"B>0?Xq" !*-< (,,8'$")$//9"('"3$%

  9. Slide 9: Transcriptional Profiling Shows Clear Differences Between HS Skin Biopsies, Healthy and Non-Lesion

    O0AL"T C$'$9"%$/*5(=$"5&"O$%(H S$9(&'"9*,-/$9"96&R" F,*0-A,%&$%+0*#(?,+.%#%0E(;4+3-(2#'*,(D%..','0A'-(@'$3''0(=;(;<%0( ,*'<"8-%$C8/*5$3" *'3"@&'H/$9(&'" -H=*/8$"l"EQEEEF!" ;&/3")6*'C$"mn"X 9*,-/$9 @%+&-C(;%$'-L(@"$(N+$(6A,+--(D%-'*-'(;'>',%$C D%..','0$%*$')(BC(D%-'*-'(;'>',%$C Non-lesion Peri-lesion

  10. Slide 10: Transcripts for Inflammatory Mediators Are Upregulated in HS Skin Lesions

    F,*0-A,%&$-(.+,(!"#$%&#'(!')%*$+,-(+.(/0.#*11*$%+0( *,'(Y&,'E"#*$')(%0(=;(;<%0(I'-%+0- Non-lesion Peri-lesion Healthy Lesion CCL2 CCL20 CSF3 CXCL1 Chemokines CXCL2 CXCL6 CXCL8 CXCL11 CXCL13 Cellular GZMB Cytotoxicity PRF1 IFNG IL10 IL1B Cytokines & IL32 Cytokine Signaling IL36G IL6 IRF7 SOCS3 TNF IL

  11. Slide 11: Proinflammatory Transcripts Correlate with IRAK4 Protein Levels in HS Skin Lesions

    !"#$%&#'(?,+%0.#*11*$+,C(F,*0-A,%&$-(2+,,'#*$'( 3%$4(/5678(?,+$'%0(I'>'#-(%0(=;(;<%0(I'-%+0- IRAK4 Lesion Correlation vs. Non-lesion IF MS CCL2 &&/ &6) &;&/ Chemokines CXCL2 CXCL6 CXCL8 &;&/ &;&/ Spearman correlation ,)1* ,/ ,/% Cytokines & ,/ Cytokine Signaling ,/* ü IL6 IRF7 ü 62&6 TNF ,/5$ Cytoki

  12. Slide 12: IRAK4 Degrader KT-474 Inhibits Induction of Inflammatory Transcripts in Healthy Controls

    /5678(D'E,*)',(7FG8H8(/04%B%$-(FI5G!')%*$')(/0)"A$%+0(+.(=;G R>',':&,'--')(?,+%0.#*11*$+,C(F,*0-A,%&$-(%0(='*#$4C(!+0+AC$'- * pS*)7"&;"?MHXeX"$;;$)5"&'"1K2II" )&'9(95$'5"R(56"1K2II".$('C" 8-95%$*,"&;"B>0?X JDEDF"?K1L>0"MNL>0OLPMB+4!"B@+Q O0AL"FD

  13. Slide 13: Conclusions

    2+0A#"-%+0- • /5678(%-(+>',':&,'--')(%0(=;(-<%0(,'#*$%>'($+(4'*#$4C(-"BW'A$-()"'($+(%0A,'*-'(%0(0"1B',(+.(/5678[()',1*#( %11"0'(A'##-(*0)('&%)',1*#(<',*$%0+AC$'- • N(C6$%"$Z-%$99(&'"('"*)5(=$"N4"97('"S$9(&'9")&,-*%$3"5&"O$%(H/$9(&'"*'3Y&%"@&'H/$9(&'"97('"*99&)(*5$3"R(56"(')%$*9$"('"(';(/5%*5('C" B>0

Kymera Therapeutics — Technical Presentation (June 2021) on 6ix